SG
BIIB icon

Swarthmore Group’s Biogen BIIB Stock Holding History

Swarthmore Group’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,100
Closed -$444K – 52
2015
Q2 		$444K Buy
1,100
+50
+5% +$20.1K 0.04% 44
2015
Q1 		$443K Buy
+1,050
New +$414K 0.04% 46

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Swarthmore Group's BIIB Position: Q3 2015 in Review

Swarthmore Group sold out of Biogen (BIIB) in Q3 2015, closing a stake of 1,100 shares — an estimated $444K sold.

Swarthmore Group first reported a position in BIIB in Q1 2015 and held it in 2 quarters. The position peaked at $444K in Q2 2015. 924 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

  • Swarthmore Group reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
  • Swarthmore Group sold 1,100 Biogen shares in Q3 2015, an estimated $444K.
  • Swarthmore Group first reported a position in Biogen in Q1 2015 and held it in 2 quarters.
  • Swarthmore Group's Biogen position peaked at $444K in Q2 2015.
  • 924 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Swarthmore Group's 13F filing for Q3 2015, filed 14 Oct 2015.